US2011076270A1PendingUtilityA1

Therapeutic Binding Molecules

46
Assignee: NOVARTIS AGPriority: Sep 18, 2003Filed: Jun 30, 2010Published: Mar 31, 2011
Est. expirySep 18, 2023(expired)· nominal 20-yr term from priority
Inventors:Gregorio AversaFrank KolbingerJose M. Carballido HerreraAndreás AszódiJose SaldanhaBruce M. Hall
A61P 37/02C07K 2317/74A61P 37/00C07K 2317/565C07K 16/289A61K 2039/505C07K 2317/24C07K 2317/92C07K 2317/75C07K 2317/73C07K 2317/56C07K 2317/41
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO comprising the polypeptide of SEQ ID NO:8 and the polypeptide of SEQ ID NO: 31. 
     
     
         2 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO comprising:
 a) a first domain comprising the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH) (SEQ ID NO:22), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) (SEQ ID NO:23) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT) (SEQ ID NO:24); and   b) a second domain comprising the hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ) (SEQ ID NO:19), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) (SEQ ID NO:20) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT) (SEQ ID NO:21).   
     
     
         3 . The isolated antibody according to  claim 2 , which is a chimeric or humanised monoclonal antibody. 
     
     
         4 . The isolated antibody or functional fragment thereof according to  claim 2 , comprising a polypeptide of SEQ ID NO: 31. 
     
     
         5 . The isolated antibody or functional fragment thereof according to  claim 2 , comprising a polypeptide of SEQ ID NO:8. 
     
     
         6 . The isolated antibody according to  claim 4  which is a chimeric monoclonal antibody. 
     
     
         7 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO which is a humanised antibody comprising a polypeptide of SEQ ID NO:8 and a polypeptide of SEQ ID NO: 31. 
     
     
         8 . A pharmaceutical composition comprising the isolated antibody or functional fragment thereof according to  claim 1  in association with at least one pharmaceutically acceptable carrier or diluent. 
     
     
         9 . A pharmaceutical composition comprising the isolated antibody or functional fragment thereof according to  claim 2  in association with at least one pharmaceutically acceptable carrier or diluent. 
     
     
         10 . The isolated antibody according to  claim 1 , which is a chimeric or humanised monoclonal antibody. 
     
     
         11 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO comprising a polypeptide of SEQ ID NO: 31. 
     
     
         12 . The isolated antibody according to  claim 11 , which is a chimeric or humanised monoclonal antibody. 
     
     
         13 . A pharmaceutical composition comprising the isolated antibody or functional fragment thereof according to  claim 11 , in association with at least one pharmaceutically acceptable carrier or diluent. 
     
     
         14 . An isolated F(ab′) 2  or Fab fragment which binds CD45RB/CD45RO comprising the polypeptide of SEQ ID NO:8 and the polypeptide of SEQ ID NO: 31. 
     
     
         15 . An isolated F(ab′) 2  or Fab fragment which binds CD45RB/CD45RO comprising:
 a) a first domain comprising the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH) (SEQ ID NO:22), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) (SEQ ID NO:23) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT) (SEQ ID NO:24); and 
 b) a second domain comprising the hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ) (SEQ ID NO:19), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) (SEQ ID NO:20) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT) (SEQ ID NO:21). 
 
     
     
         16 . The isolated F(ab′) 2  or Fab fragment according to  claim 15 , comprising a polypeptide of SEQ ID NO: 31. 
     
     
         17 . The isolated F(ab′) 2  or Fab fragment according to  claim 15 , comprising a polypeptide of SEQ ID NO:8. 
     
     
         18 . A pharmaceutical composition comprising the isolated F(ab′) 2  or Fab fragment according to  claim 14  in association with at least one pharmaceutically acceptable carrier or diluent.

Join the waitlist — get patent alerts

Track US2011076270A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.